Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam
Pharma
Alnylam's last-minute Amvuttra trial change raises doubts
Alnylam changed the analysis plan for the closely watched HELIOS-B trial just before an expected readout, triggering a 8% drop in its stock price.
Angus Liu
Feb 15, 2024 11:26am
JPM24, Day 2: Lilly, Novo, Sanofi, Sarepta, Merck and more
Jan 9, 2024 8:30pm
FDA spurns Alnylam's Onpattro in ATTR-CM despite adcomm backing
Oct 9, 2023 9:54am
Novo Nordisk eyes showdown with Alnylam with new FDA nod
Oct 2, 2023 1:36pm
Pfizer's tafamidis will hold its own against new meds: analysts
Sep 18, 2023 3:05pm
Alnylam wins expert backing for Onpattro in rare heart disease
Sep 13, 2023 5:30pm